Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma.
Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, LaPelusa M, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Amin HM, Kaseb AO. Chamseddine S, et al. J Immunother Precis Oncol. 2024 Nov 1;7(4):255-262. doi: 10.36401/JIPO-24-6. eCollection 2024 Nov. J Immunother Precis Oncol. 2024. PMID: 39524465 Free PMC article.
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma.
LaPelusa M, Chamseddine S, Tran Cao HS, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. LaPelusa M, et al. Among authors: chamseddine s. Oncology. 2024 Oct 18:1-8. doi: 10.1159/000541250. Online ahead of print. Oncology. 2024. PMID: 39427654 Free article.
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab.
Mohamed YI, Lee SS, Demir T, Chamseddine S, Hu ZI, Xiao L, Elsayes K, Morris JS, Wolff RA, Hiatia R, Qayyum A, Rashid A, Duda DG, Yao JC, LaPelusa M, Koay EJ, Mahvash A, Al Azzam A, Dumbrava EE, Hassan M, Amin HM, Kaseb AO. Mohamed YI, et al. Among authors: chamseddine s. Cancer Biomark. 2024;41(1):83-91. doi: 10.3233/CBM-230431. Cancer Biomark. 2024. PMID: 39269823 Free PMC article.
Characteristics of medically attended influenza infection across age groups before the COVID-19 pandemic in Lebanon.
Haddara A, Houry Z, Zahreddine N, Atallah M, Boutros CF, Tannous J, Sadaka C, Wehbe S, Kadi T, Ibrahim A, Ahmadieh R, Kardas T, Soudani N, Kalamouni HA, Zgheib Y, Yaman NE, Khafaja S, Lteif M, Shaker R, Casals AA, Youssef Y, Youssef N, Zein ZE, Chamseddine S, Chmaisse A, Haj M, Fayad D, Kiblawi S, Isaac I, Anan H, Radwan N, Wakim RH, Zaraket H, Kanj SS, Dbaibo GS. Haddara A, et al. Among authors: chamseddine s. J Infect Public Health. 2024 Sep;17(9):102521. doi: 10.1016/j.jiph.2024.102521. Epub 2024 Aug 14. J Infect Public Health. 2024. PMID: 39173555 Free article.
Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.
Chamseddine S, LaPelusa M, Carter K, Nguyen V, Mohamed YI, Sakr Y, Rojas-Hernandez CM, Hatia RI, Hassan M, Goss JA, Elsayes KM, Rashid A, Sun R, Tran Cao HS, Amin HM, Kaseb AO. Chamseddine S, et al. J Gastrointest Oncol. 2024 Jun 30;15(3):1324-1330. doi: 10.21037/jgo-24-290. Epub 2024 Jun 19. J Gastrointest Oncol. 2024. PMID: 38989410 Free PMC article.
Integrating circulating T follicular memory cells and autoantibody repertoires for characterization of autoimmune disorders.
Harris EM, Chamseddine S, Chu A, Senkpeil L, Nikiciuk M, Al-Musa A, Woods B, Ozdogan E, Saker S, van Konijnenburg DPH, Yee CSK, Nelson R, Lee P, Halyabar O, Hale RC, Day-Lewis M, Henderson LA, Nguyen AA, Elkins M, Ohsumi TK, Gutierrez-Arcelus M, Peyper JM, Platt CD, Grace RF, LaBere B, Chou J. Harris EM, et al. Among authors: chamseddine s. medRxiv [Preprint]. 2024 Mar 7:2024.02.25.24303331. doi: 10.1101/2024.02.25.24303331. medRxiv. 2024. PMID: 38464255 Free PMC article. Preprint.
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.
Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Che J, Nishida N, Lee PC, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietharn B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M. Balcar L, et al. Among authors: chamseddine s. JHEP Rep. 2023 Dec 12;6(2):100982. doi: 10.1016/j.jhepr.2023.100982. eCollection 2024 Feb. JHEP Rep. 2023. PMID: 38274490 Free PMC article.
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Joerg V, Scheiner B, D Alessio A, Fulgenzi CAM, Schönlein M, Kocheise L, Lohse AW, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal YI, Chamseddine S, Phen S, Cheon J, Lee PC, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang YH, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal AG, Chon HJ, Pinato DJ, Schulze K, von Felden J. Joerg V, et al. Among authors: chamseddine s. Hepatol Commun. 2023 Oct 27;7(11):e0302. doi: 10.1097/HC9.0000000000000302. eCollection 2023 Nov 1. Hepatol Commun. 2023. PMID: 37889520 Free PMC article.
24 results